Endoscopic Injection of Recombinant Human Adenovirus Type 5 Combined with Chemotherapy in the Treatment of Gastric Cancer: A Case Report

  • Guidong Jiang Dalian Medical University
  • Doudou Hu Qingdao Municipal Hospital
  • Xiangjun Jiang Qingdao Municipal Hospital
DOI: https://doi.org/10.18686/aem.v11i3.288
Keywords: Gastric Cancer, Adenovirus, Chemotherapy, Case-Reporting

Abstract

Purpose: To investigate the endoscopic injection of recombinant human adenovirus type 5 (H101) in the treatment of gastric cancer. Method: The diagnosis and treatment data of one patient with advanced gastric cancer were collected and discussed. Result: The patient ,a 51-year-old middle-aged male, was diagnosed with gastric malignant tumor (adenocarcinoma stage IV) with liver metastasis and lymph node metastasis combined with the results of gastroscopy, imaging and pathological examination. The patient underwent endoscopic injection of recombinant human adenovirus type 5 (H101) and chemotherapy.After 4 times of endoscopic treatment, the patient had no serious adverse reactions,pyloric obstruction was relieved, carcinoembryonic antigen was significantly reduced, intragastric ulcerated-like tumor was healed,the range of liver metastases was reduced.In outpatient follow-up, no tumor recurrence or metastasis was found, and the general condition was good. Conclusion: Endoscopic injection of recombinant human adenovirus type 5 showed good efficacy and safety and tolerability in patients with advanced gastric cancer.It is worthy of further promotion in clinical practice.

References

[1] Hyuna Sung, PhD, Jacques Ferlay, MSc, ME, Rebecca L. Siegel, MPH, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA CANCER J CLIN 2021; 71: 209–249.

[2] Rogulski KR, Freytag SO, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy[J]. Cancer Res, 2000, 60(5):1193-1196.

[3] WHO. Globocan 2020 Stomach. In: WHO, Globocan 2020 China. China:International Agency for Research on Cancer. March 2021. Available at:https://gco.iarc.fr/today/data/factsheets/ cancers/7-Stomach-fact-sheet.pdf2.

[4] Nakagawa N, Kanda M, Ito S, et al. Pathological tumor infiltrative pattern and sites of initial recurrence in stage II/III gastric cancer: propensity score matching analysis of a multi-institutional dataset. Cancer Med. 2018;7(12):6020–9.

[5] Kim JH, Lee HH, Seo HS, et al. Borrmann type 1 Cancer is associated with a high recurrence rate in locally advanced gastric Cancer. Ann Surg Oncol.2018;25(7):2044–52.

[6] Chan BA, Jang RW, Wong RK, Swallow CJ, Darling GE, Elimova E. Improving Outcomes in Resectable Gastric Cancer: A Review of Current and Future Strategies. Oncology (Williston Park). 2016; 30: 635-645.

[7] Ozge Gumusay, Mustafa Benekli, Ozgur Ekinci, Meltem Baykara, Ahmet Ozet, Ugur Coskun, Umut Demirci, Aytug Uner, Ayse Dursun, Ecine Yesim Atak, Suleyman Buyukberber, Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites, Japanese Journal of Clinical Oncology, Volume 45, Issue 5, May 2015, Pages 416–421.

[8] Elias R, Karantanos T, Sira E, Hartshorn KL. Immunotherapy comes of age: Immune aging & checkpoint inhibitors. J Geriatr Oncol. 2017 May;8(3):229-235.

[9] Saeed SM, Bilal S, Siddique MZ, Saqib M, Shahid S, Ghumman AN, Yusuf MA. Pyloric stent insertion in malignant gastric outlet obstruction: moving beyond palliation. Ther Adv Gastrointest Endosc. 2021 Sep 25;14:26317745211047012.

[10] Kim DY, Moon HS, Kwon IS, Park JH, Kim JS, Kang SH, Lee ES, Kim SH, Lee BS, Sung JK, Jeong HY. Self-expandable metal stent of esophagogastric junction versus pyloric area obstruction in advanced gastric cancer patients: Retrospective, comparative, single-center study. Medicine (Baltimore). 2020 Aug 14;99(33):e21621.

[11] Zhong, DT, Wu, RP, Wang, XL, Huang, XB, Lin, MX, Lan, YQ, & Chen, Q, Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer；Pathol. Oncol. Res. (2015) 21:867–873.

[12] Lee KW, Chung IJ, Ryu MH, Park YI, Nam BH, Oh HS, Lee KH, Han HS, Seo BG, Jo JC, Lee HR, Kim JW, Park SR, Cho SH, Kang YK; SOPP study investigators. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer. 2021 Jan;24(1):156-167.

[13] Zhang, R, Cui, YX, Guan, X, and Jiang, XJ, A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study. Gastrointestinal Cancers.

[14] Lobke CM. Hensen, Rob C. Hoeben and Selas TF. Bots. Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy.Molecular Sciences.Int. J. Mol. Sci. 2020, 21, 6828.

[15] Chen, GX, Zheng, LH, Liu, SY, He, XH., rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherap.World J Gastroenterol 2011 October 14; 17(38): 4289-4297 ISSN 1007-9327 (print) ISSN 2219-2840 (online).

[16] Ki, SH, Jeong, S., Park, IS, Lee, DH, Lee, JI, Kwon, KS, Kim, HG, & Shin, YW, Esophageal mucosal metastasis from adenocarcinoma of the distal stomach, World J Gastroenterol 2013 June 21; 19(23): 3699-3702.

[17] Kuball J, Wen SF, Leissner J, Atkins D, Meinhardt P, Schuler M. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.J Clin Oncol 2002; 20: 957-965.
Published
2022-11-07
Issue
Vol 11 No 3 (2022)
Section
Original Research Article

Copyright (c) 2022 Guidong Jiang, Doudou Hu, Xiangjun Jiang

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.